IOVA Jumps 33.8% on Raised 2026 Outlook; CBRL, AMAT Lead EPS Revision Rally
Iovance Biotherapeutics (IOVA) surged 33.8% to $14.45 after raising FY2026 revenue guidance to $410-$420 million, a $55 million midpoint increase that cleared consensus. Cracker Barrel (CBRL) added 17.0% to $52.48 following Q4 adjusted EBITDA of $62.1 million and upbeat FY2027 guidance. Applied Materials (AMAT) rose 10.3% to $512.01 as AI capex and services growth kept semiconductor spending in focus.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| IOVA | Healthcare | 2026-09-24 | N/A | +33.8% |
| CBRL | Consumer Cyclical | 2026-09-21 | +1358.0pp | +17.0% |
| LIND | Consumer Cyclical | 2026-09-21 | N/A | +10.5% |
| AMAT | Technology | 2026-09-21 | N/A | +10.3% |
| NNBR | Industrials | 2026-09-24 | +1.8pp | +7.8% |
Why did IOVA stock jump in September 2026?
IOVA jumped 33.8% to $14.45 after the company raised its FY2026 revenue outlook to $410–$420 million on September 29, up from $350–$370 million, a $55 million midpoint increase.
The upward revision, which cleared the $402.8 million consensus, followed record Q2 product revenue of $99.3 million, driven by $89.5 million in Amtagvi and $9.8 million in Proleukin sales. Management cited increasing patient demand and a well-aligned manufacturing schedule, with its authorized treatment center network nearing 100 locations and targeting 110 by year-end. The screener detected IOVA on September 24 at $10.80, and the stock hit over two-year highs as the revenue guidance hike confirmed the positive EPS revision signal.
IOVA EPS revision history → · Screener snapshot from 2026-09-24 →
FAQ: IOVA
Why did IOVA stock jump on September 29, 2026?
Iovance raised its FY2026 revenue guidance to $410–$420 million from $350–$370 million, a $55 million midpoint increase that exceeded the $402.8 million consensus, sending shares up 33.8% to $14.45.
Is IOVA a buy after its recent rally?
The raised guidance implies nearly 60% annual revenue growth, and with Q3 results due in November and expansion into lung and endometrial cancers underway, the fundamental story remains strong, though the sharp 33.8% move may warrant caution on entry price.
What is Iovance's EPS growth estimate for next year?
Iovance's current EPS growth estimate for next year is 52.0%, as reflected in the EPS revision screener that detected the stock on September 24, 2026.
Why did CBRL stock jump in September 2026?
CBRL jumped 17.0% to $52.48 after reporting Q4 2026 adjusted EBITDA of $62.1 million on September 24, up 11.4% year-over-year and ahead of expectations.
The earnings beat was reinforced by a massive upward revision to next-year EPS growth estimates, which surged from 2453.4% to 3811.4%—a 1358.0 percentage point increase—after the company guided FY2027 adjusted EBITDA to $180–$200 million. Guest metrics improved significantly, with food taste and service scores up nearly 400 basis points, while the loyalty program surpassed 12.5 million members and accounted for over 40% of tracked sales. The screener detected CBRL on September 21 at $44.87, capturing the stock before the post-earnings rally as the market confirmed the earnings revision.
CBRL EPS revision history → · Screener snapshot from 2026-09-21 →
FAQ: CBRL
Why did CBRL stock surge after Q4 earnings?
Cracker Barrel reported Q4 adjusted EBITDA of $62.1 million, up 11.4% year-over-year, and issued FY2027 guidance projecting adjusted EBITDA of $180–$200 million, driving a 17.0% gain to $52.48.
What caused Cracker Barrel's EPS estimate revision?
The EPS growth estimate for next year was revised upward from 2453.4% to 3811.4% following the Q4 earnings beat and strong FY2027 guidance that implied a $30–$50 million EBITDA step-up.
Is CBRL a buy after the recent rally?
The company reduced total debt by $147.4 million year-over-year and showed improving guest metrics and retail sales, but investors should weigh the 17.0% recent gain and still-negative comparable restaurant sales of -2.1%.
Why did LIND stock jump in September 2026?
LIND jumped 10.5% to $31.27 after its next-year EPS growth estimate was revised to 159.6% following the screener's detection on September 21 at $28.29.
No company-specific news was found in the window, so the move appears driven by sector momentum in travel and expedition cruising, where demand for experiential leisure remains resilient. The absence of negative catalysts and a high EPS growth estimate likely attracted momentum buyers, amplifying the price gain. As a small-cap consumer cyclical, Lindblad benefited from broader market strength in discretionary travel names during late September 2026.
LIND EPS revision history → · Screener snapshot from 2026-09-21 →
FAQ: LIND
Why did LIND stock rise in September 2026?
Lindblad Expeditions gained 10.5% to $31.27 after its next-year EPS growth estimate was revised to 159.6%, detected by the screener on September 21, with the move supported by sector momentum in experiential travel.
What is LIND's EPS growth estimate?
LIND's current EPS growth estimate for next year is 159.6%, up from the prior estimate, as captured by the EPS revision screener.
Is LIND a buy after its recent surge?
With no company-specific news in the period, the rally appears momentum-driven; investors should monitor upcoming earnings for confirmation of the 159.6% EPS growth estimate.
Why did AMAT stock jump in September 2026?
AMAT jumped 10.3% to $512.01 after its next-year EPS growth estimate was revised to 46.1%, with the stock detected by the screener on September 21 at $464.24.
The gain was reinforced by AI-driven semiconductor capex trends, as Morningstar cited Goldman Sachs projecting S&P 500 earnings to rise 26% in Q3, with Applied Materials among the companies in focus for AI infrastructure spending. The company's services business, Applied Global Services, grew 22% year-over-year to a record $1.8 billion in fiscal Q3 2026, representing about 20% of total revenue and providing a stable growth vector. The combination of a strong EPS revision and positive AI sector news helped AMAT recover from a 27% three-month decline prior to detection.
AMAT EPS revision history → · Screener snapshot from 2026-09-21 →
FAQ: AMAT
Why did AMAT stock jump in late September 2026?
Applied Materials rose 10.3% to $512.01 after its next-year EPS growth estimate was revised to 46.1% and AI capex news highlighted semiconductor equipment demand, following a 27% three-month decline.
What is AMAT's EPS growth estimate for next year?
AMAT's current EPS growth estimate for next year is 46.1%, as detected by the EPS revision screener on September 21, 2026.
Is AMAT a buy after the recent rally?
The services segment grew 22% year-over-year to a record $1.8 billion in fiscal Q3 2026, and with AI capex projected to remain strong, the stock's rebound may have further room, though chip spending cycles remain a risk.
Why did NNBR stock jump in September 2026?
NNBR jumped 7.8% to $3.88 after its next-year EPS growth estimate was revised upward from 71.0% to 72.7% on September 24, when the stock was detected at $3.60.
The small-cap industrial, which specializes in precision components, benefited from a modest but positive estimate revision amid a stable manufacturing environment. With no company-specific news, the gain likely reflects broader sector strength and the screener's early capture of the upward EPS revision. The 1.8 percentage point revision, while small, was enough to attract attention given NNBR's low price and high growth estimate.
NNBR EPS revision history → · Screener snapshot from 2026-09-24 →
FAQ: NNBR
Why did NNBR stock rise in September 2026?
NN Inc gained 7.8% to $3.88 after its next-year EPS growth estimate was revised from 71.0% to 72.7% on September 24, with the move supported by general industrial sector stability.
What is NNBR's EPS growth estimate?
NNBR's current EPS growth estimate for next year is 72.7%, revised upward from 71.0% on September 24, 2026.
Is NNBR a buy after the recent gain?
The upward EPS revision is a positive signal, but with no company-specific news, investors should await further fundamental catalysts before making a decision.
Today's top performers—IOVA, CBRL, and AMAT—show that upward EPS revisions, when confirmed by strong earnings or guidance, can drive significant gains across healthcare, consumer, and technology. The market is rewarding companies that beat expectations and raise outlooks, signaling continued optimism in sectors tied to AI infrastructure and experiential demand.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →